NR3C1 (nuclear receptor subfamily 3 group C member 1, the glucocorticoid receptor; HGNC:7978, NCBI Gene 2908) is the gene on chromosome 5q31.3 encoding the glucocorticoid receptor (GR) — the nuclear receptor that cortisol (and every glucocorticoid drug) binds: ligand binding releases the chaperone complex, exposes the nuclear-localisation and DNA-binding domains, and the receptor binds glucocorticoid-response elements to repress inflammatory gene programs and induce metabolic ones. Every corticosteroid's therapeutic action and side-effect runs through it.
Approved Symbol
NR3C1 (HGNC:7978)
Chromosomal Locus
5q31.3
Encoded Product
GRα — a 97-kDa nuclear receptor (777 aa) + the GRβ dominant-negative isoform
Primary Pathway
Cortisol → GR → GRE gene regulation (transrepression of NF-κB/AP-1; metabolic transactivation)
Clinical / Therapeutic Role
Generalized glucocorticoid resistance (Chrousos); corticosteroid-response genetics; the ER3629 variant
Gene Structure & Expression
Genomic organization: Nine exons with alternative splicing (GRα active, GRβ dominant-negative; the A–D N-terminal variants) and the polymorphisms (ER9β, N363S, ER3629/6β) studied in corticosteroid-response pharmacogenetics.
Expression: Nearly universal — the receptor being present wherever cortisol acts (all immune cells, liver, muscle, brain); tissue response set by isoform mix, 11β-HSD2's local-cortisol activation, and co-regulator availability.
Molecular Function & Pathways
Transrepression and transactivation: GR's anti-inflammatory action (protein-protein inhibition of NF-κB and AP-1) versus its metabolic program (gluconeogenesis induction via PEPCK, muscle catabolism, bone loss) — the two faces that inhaled-and-selective steroid design tries to separate.
Feedback axis: Hippocampal and hypothalamic GR mediating cortisol's negative feedback on the HPA axis — the receptor whose sensitivity sets the stress axis's set-point; CRH upstream.
Clinical & Therapeutic Significance
Clinical genetics: Generalized glucocorticoid resistance (Chrousos syndrome) — hypercortisolism without Cushingoid features, with mineralocorticoid and androgen excess; GR polymorphisms modifying corticosteroid response in asthma, transplantation, and rheumatologic disease.
Pharmacology: Dexamethasone-suppression testing (Cushing's differential); glucocorticoid sensitivity/resistance phenotypes; the chronic-steroid side-effect profile (diabetes, osteoporosis — see bone biology) as on-target toxicity.